Status:
COMPLETED
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
Eligibility Criteria
Inclusion
- Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
- Able to give informed consent. Patient' s caregiver must consent to participate in the study.
Exclusion
- Use of medications for cognitive enhancement within 3 months of baseline.
- Significant neurologic disease other than AD that may affect cognition.
Key Trial Info
Start Date :
October 6 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2008
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT00151398
Start Date
October 6 2005
End Date
March 15 2008
Last Update
May 6 2022
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85013
2
Tucson, Arizona, United States, 85741
3
Costa Mesa, California, United States, 92626
4
Fresno, California, United States, 93720